The waveLINE-003 trial demonstrates the efficacy of zilovertamab vedotin combined with standard therapy, with manageable safety profiles in difficult-to-treat DLBCL patients. ADCs provide logistical ...

The company has moved and is now on 31 acres of peaceful countryside — a sanctuary that invites guests into an immersive ...

Federal prosecutors have unveiled charges against six more people accused of defrauding programs in Minnesota — adding to a ...

Law enforcement released photos of a person “in proximity of the person of interest” in the shooting and a map showing where ...

The U.S. Department of Health and Human Services on Thursday unveiled a series of regulatory actions designed to effectively ...

Curasight A/S ("Curasight" or "the Company" – TICKER: CURAS) today announced the successful and safe dosing of the first patient in the Phase 1 trial using uTREAT in brain cancer (high grade gliomas).

Equity Insider News Commentary – The oncology sector's pivot toward platform-based precision therapies has signaled smart money ...

Wellness tourism is projected to reach $1.3 trillion by 2028, but the experience itself looks far different from what it did ...

A child who received the world's first personalized CRISPR therapy is now taking his first steps after months in hospital ...

Significant treatment options are changing the management of CLL, according to research presented at the ASH Annual Meeting 2025.

Miguel-Angel Perales, MD, spoke with Targeted Oncology® about the problems the CAR T Vision group has identified and the key ...